Academic Journal
Improved breast cancer diagnosis using a CA15-3 capture antibody-lectin sandwich assay
| Τίτλος: | Improved breast cancer diagnosis using a CA15-3 capture antibody-lectin sandwich assay |
|---|---|
| Συγγραφείς: | Nikseresht, S, Shewell, LK, Day, CJ, Jennings, MP, Chittoory, H, McCart Reed, AE, Simpson, PT, Lakhani, SR, Nabiee, R, Moore, M, Khanabdali, R, Hinch, LM, Rice, GE |
| Στοιχεία εκδότη: | Springer |
| Έτος έκδοσης: | 2025 |
| Συλλογή: | Griffith University: Griffith Research Online |
| Θεματικοί όροι: | Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical sciences |
| Περιγραφή: | Purpose This study aims to test the hypothesis that an enzyme-linked antibody-lectin sandwich assay for a glycovariant of CA15-3 can deliver better diagnostic performance, defined by classification accuracy, sensitivity and specificity, for breast cancer compared to an existing FDA-approved CA15-3 test. Methods A genetically engineered lectin (SubB2M) that specifically binds N-glycolylneuraminic acid (Neu5Gc) was used as a detection reagent in a CA15-3 capture antibody-lectin sandwich (neuCA15-3) assay. In a case: control cohort equivalence study the classification accuracy for the neuCA15-3 assay was determined and compared to an FDA-approved CA15-3 IVD test (Elecsys CA15-3 II, Roche Diagnostics). Results Classification accuracy and AUC for neuCA15-3 were 81% and 0.886 ± 0.015 (standard error, n = 567) and for Elecsys CA15-3 II, 55% and 0.642 ± 0.023 (n = 558), respectively. At a threshold cut-off serum concentration of 23.6 units/ml, overall breast cancer classification accuracy of the neuCA15-3 was 81% (compared to 55% for the comparator assay, p < 0.001). At 95% specificity, the sensitivity of the neuCA15-3 assay was 69.5%, significantly greater than the comparator assay (11.9%, p < 0.001). neuCA15-3 concentrations did not vary significantly with breast cancer receptor subtype or comorbidities tested. Conclusions The diagnostic performance of neuCA15-3 was substantially improved by specifically targeting both a CA15-3 protein epitope and a pan-cancer glycan (Neu5Gc) epitope (the specific binding target of SubB2M). The reporter signal generated depends on the colocalization of the cancer antigen protein epitope and the aberrant sialylation of the protein, thus increasing the assay specificity. The presence of multiple Neu5Gc lectin-binding sites per glycoprotein molecule increases signal generation and assay sensitivity. The inclusion of additional cancer biomarkers in a multivariate index assay format may further increase diagnostic performance for breast cancer. ; Full Text |
| Τύπος εγγράφου: | article in journal/newspaper |
| Γλώσσα: | English |
| Relation: | Breast Cancer Research and Treatment; Nikseresht, S; Shewell, LK; Day, CJ; Jennings, MP; Chittoory, H; McCart Reed, AE; Simpson, PT; Lakhani, SR; Nabiee, R; Moore, M; Khanabdali, R; Hinch, LM; Rice, GE, Improved breast cancer diagnosis using a CA15-3 capture antibody-lectin sandwich assay, Breast Cancer Research and Treatment, 2025, 211 (3), pp. 605-615; https://hdl.handle.net/10072/436960 |
| DOI: | 10.1007/s10549-025-07672-z |
| Διαθεσιμότητα: | https://hdl.handle.net/10072/436960 https://doi.org/10.1007/s10549-025-07672-z |
| Rights: | https://creativecommons.org/licenses/by/4.0/ ; This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. ; open access |
| Αριθμός Καταχώρησης: | edsbas.D4F7103F |
| Βάση Δεδομένων: | BASE |
καταχωρήστε σχόλιο πρώτοι!